Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer
Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
platinum-based albumin-bound paclitaxel regimen in advanced non-small cell lung cancer
(NSCLC) especially in lung squamous cell carcinoma has a better tumor response rate and
safety than solvent-based paclitaxel.However, the safety and efficacy is uncertain in
neoadjuvant therapy.